Floatz logo

Tabelecleucel

Stem Cell Transplant Complications

Pierre Fabre MedicamentCell therapyPhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

74 Active assets in the Stem Cell Transplant Complications cohort.

Asset / SponsorPhaseRating
Busulphan
Institute of Hematology & Blood Diseases Hospital, China
Phase 3BBB
Cyclophosphamide
The First Affiliated Hospital of Soochow University
Phase 3BBB
FILGRASTIM
National Cancer Institute (NCI)
Phase 2/3BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
M.D. Anderson Cancer Center
Phase 2BBB
Decitabine
Chinese PLA General Hospital
Phase 4BBB

View all 50 →

Same molecule, other indications

Tabelecleucel is also rated in:

Epstein-Barr virus-associated lymphoproliferative disorderDormant
BB
Indicative ·
66 / 100
View asset →
disease related to hematopoietic stem cell transplantDormant
BB
Indicative ·
66 / 100
View asset →
Solid Organ Transplant ComplicationsDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →